David Michael Clark net worth and biography

David Clark Biography and Net Worth

Insider of Amicus Therapeutics

David Clark serves as Chief People Officer of the Company. Mr. Clark was previously Vice President of Global Human Resources at Alibaba Group, headquartered in Hangzhou, China, from September 2016 to August 2018. Prior to that, David spent eight years at American Express, where he was Senior Vice President of Human Resources (HR) and Chief Learning Officer. While there, David was a senior HR Business Partner and led the transformation of learning, leadership development and performance management. Previously, David was a Commissioned Officer on the White House senior staff. As Deputy Assistant to the President of the United States, he led the recruitment and development of the 4,000 most senior leaders in the U.S. government. David received a B.S. in political science from Indiana State University. He is an Eagle Scout and serves on the National Executive Board of the Boy Scouts of America. David is also the Chairman of the Board of the Make-A-Wish Foundation of America.

What is David Michael Clark's net worth?: The estimated net worth of David Michael Clark is at least $2.49 million as of February 15th, 2024. Mr. Clark owns 253,664 shares of Amicus Therapeutics stock worth more than $2,485,907 as of December 21st. This net worth estimate does not reflect any other assets that Mr. Clark may own. Additionally, Mr. Clark receives a salary of $701,390.00 as Insider at Amicus Therapeutics. Learn More about David Michael Clark's net worth.
How old is David Michael Clark?: Mr. Clark is currently 49 years old. There are 5 older executives and no younger executives at Amicus Therapeutics. The oldest executive at Amicus Therapeutics is Mr. Simon Nicolas Reade Harford, Chief Financial Officer, who is 64 years old. Learn More on David Michael Clark's age.
What is David Michael Clark's salary?: As the Insider of Amicus Therapeutics, Inc., Mr. Clark earns $701,390.00 per year. There are 3 executives that earn more than Mr. Clark. The highest earning executive at Amicus Therapeutics is Mr. Bradley L. Campbell M.B.A., CEO, President & Director, who commands a salary of $984,090.00 per year. Learn More on David Michael Clark's salary.
How do I contact David Michael Clark?: The corporate mailing address for Mr. Clark and other Amicus Therapeutics executives is 1 Cedar Brook Drive, Cranbury NJ, 08512. Amicus Therapeutics can also be reached via phone at (215) 921-7600 and via email at [email protected]. Learn More on David Michael Clark's contact information.
Has David Michael Clark been buying or selling shares of Amicus Therapeutics?: David Michael Clark has not been actively trading shares of Amicus Therapeutics during the past quarter. Most recently, David Michael Clark sold 4,427 shares of the business's stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $14.00, for a transaction totalling $61,978.00. Following the completion of the sale, the insider now directly owns 253,664 shares of the company's stock, valued at $3,551,296. Learn More on David Michael Clark's trading history.
Who are Amicus Therapeutics' active insiders?: Amicus Therapeutics' insider roster includes Lynn Bleil (Director), Bradley Campbell (CEO), Bradley Campbell (CEO), Jeff Castelli (Insider), David Clark (Insider), John Crowley (Chairman Emeritus), Margaret Mcglynn (Director), Samantha Prout (Insider), Michael Raab (Director), Ellen Rosenberg (Insider), Ellen Rosenberg (Insider), and Burke Whitman (Director). Learn More on Amicus Therapeutics' active insiders.
Are insiders buying or selling shares of Amicus Therapeutics?: During the last year, insiders at the biopharmaceutical company sold shares 22 times. They sold a total of 316,307 shares worth more than $4,102,561.17. The most recent insider tranaction occured on December, 2nd when CEO Bradley L Campbell sold 7,500 shares worth more than $75,150.00. Insiders at Amicus Therapeutics own 2.2% of the company. Learn More about insider trades at Amicus Therapeutics.
Information on this page was last updated on 12/2/2024.

David Michael Clark Insider Trading History at Amicus Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/15/2024	Sell	4,427	$14.00	$61,978.00	253,664
1/9/2024	Sell	1,384	$14.00	$19,376.00	266,705
1/18/2023	Sell	7,382	$13.50	$99,657.00	241,067
1/6/2023	Sell	21,507	$11.87	$255,288.09	219,566
1/3/2023	Sell	8,493	$12.03	$102,170.79	190,203

David Michael Clark Buying and Selling Activity at Amicus Therapeutics

Amicus Therapeutics Company Overview

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Today's Range

Now: $9.80

$9.60

$9.88

50 Day Range

MA: $10.48

$9.36

$12.01

2 Week Range

Now: $9.80

$9.02

$14.57

Volume

4,077,524 shs

Average Volume

2,724,375 shs

Market Capitalization

$2.93 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.6

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."

I put all the details together for you here — but please hurry.

David Clark Biography and Net Worth

What is David Michael Clark's net worth?

How old is David Michael Clark?

What is David Michael Clark's salary?

How do I contact David Michael Clark?

Has David Michael Clark been buying or selling shares of Amicus Therapeutics?

Who are Amicus Therapeutics' active insiders?

Are insiders buying or selling shares of Amicus Therapeutics?